8-K: Iterum Therapeutics Announces Second Quarter 2024 Financial Results and Provides Regulatory Update

Iterum Therapeutics reported its second quarter 2024 financial results, highlighted by a PDUFA action date of October 25, 2024, for its oral sulopenem NDA and an upcoming Advisory Committee meeting on September 9, 2024.

Summary

• Iterum Therapeutics announced its financial results for the second quarter of 2024, ending June 30, 2024.
• The company's cash, cash equivalents, and short-term investments totaled $11.7 million as of June 30, 2024.
• Iterum expects its current cash resources, including proceeds from a recent rights offering, to fund operations into 2025, including through the PDUFA date.
• Research and development expenses decreased to $2.1 million in Q2 2024 from $9.0 million in Q2 2023, primarily due to the completion of the REASSURE trial.
• General and administrative expenses remained stable at $1.9 million for both Q2 2024 and Q2 2023.
• The net loss for Q2 2024 was $5.0 million, compared to a net loss of $12.2 million for the same period in 2023.
• Non-GAAP net loss for Q2 2024 was $3.8 million, compared to a non-GAAP net loss of $10.0 million in 2023.
• The FDA has set a PDUFA action date of October 25, 2024, for the resubmitted NDA for oral sulopenem.
• An Advisory Committee meeting is scheduled for September 9, 2024, to discuss antimicrobial stewardship and the target patient population for oral sulopenem.
• Iterum completed a rights offering on August 9, 2024, raising $7.4 million in gross proceeds ($5.8 million net).
• The company received Notices of Allowance for three patents related to sulopenem combinations in the US and Canada.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in the regulatory process, the successful rights offering, and the reduction in losses. However, the upcoming Advisory Committee meeting and the company's ongoing losses introduce some uncertainty.

Positives

• The company has a clear PDUFA action date for its key drug candidate, oral sulopenem.
• The recent rights offering has strengthened the company's financial position.
• The company has secured patent allowances for its sulopenem combinations, extending intellectual property protection.
• The company has significantly reduced its net loss and R&D expenses compared to the same period last year.
• The company's cash runway is sufficient to fund operations into 2025, including through the PDUFA date.

Negatives

• The FDA has scheduled an Advisory Committee meeting to discuss antimicrobial stewardship and target patient populations, which could indicate potential concerns.
• The company is still operating at a loss, although the loss has decreased compared to the previous year.
• The company's cash balance has decreased from $23.9 million at the end of 2023 to $11.7 million as of June 30, 2024.

Risks

• The FDA Advisory Committee meeting could raise concerns that may impact the approval of oral sulopenem.
• The company's ability to achieve profitability is dependent on the successful commercialization of sulopenem.
• The company's cash resources may not be sufficient to fund operations beyond 2025.
• There are risks associated with the strategic process to sell, license, or dispose of rights to sulopenem.
• The company's ability to regain and maintain its listing on the Nasdaq Capital Market is not guaranteed.

Future Outlook

Iterum expects its current cash resources to fund operations into 2025, including through the PDUFA date. The company is also pursuing a strategic process to maximize the value of sulopenem.

Management Comments

• Corey Fishman, Iterum's CEO, stated that the proceeds from the rights offering allow the company to continue to pursue its business plan and strategy.
• Corey Fishman also mentioned that the company is working with the FDA during the review of the resubmitted NDA for oral sulopenem, including preparing for the Advisory Committee meeting.

Industry Context

The development of new antibiotics is crucial due to the increasing threat of multi-drug resistant pathogens. Iterum's sulopenem, if approved, would be the first oral penem antibiotic in the U.S., addressing a significant unmet need in the treatment of urinary tract infections.

Comparison to Industry Standards

• The decrease in R&D expenses from $9.0 million to $2.1 million quarter-over-quarter is significant and suggests a shift from active clinical trial spending to regulatory and pre-commercialization activities, which is typical for a company nearing a potential drug approval.
• The net loss reduction from $12.2 million to $5.0 million is a positive sign, indicating improved cost management and operational efficiency.
• Companies like Nabriva Therapeutics and Achaogen, which also focused on novel antibiotics, faced challenges in commercialization and market adoption, highlighting the risks Iterum faces despite the positive regulatory progress.
• The upcoming Advisory Committee meeting is a critical milestone, as similar meetings for other novel antibiotics have sometimes resulted in delays or non-approvals, such as with Achaogen's plazomicin.

Stakeholder Impact

• Shareholders will be impacted by the potential approval of sulopenem and the company's financial performance.
• Employees are affected by the company's financial stability and future prospects.
• Patients could benefit from the availability of a new treatment option for urinary tract infections.
• Creditors are impacted by the company's ability to repay its debts.

Next Steps

• Iterum will participate in the FDA Advisory Committee meeting on September 9, 2024.
• The company awaits the FDA's decision on its NDA for oral sulopenem by the PDUFA action date of October 25, 2024.
• Iterum will continue its strategic process to maximize the value of sulopenem.

Key Dates

Keywords

Iterum Therapeutics, sulopenem, FDA, PDUFA, Advisory Committee, rights offering, antibiotics, uUTI, patent, financial results